A digital-first life sciences firm invests Rs 3.24 crore in community initiatives, surpassing mandates while driving healthcare equity and sustainability.
NEW DELHI (India CSR): In a testament to its unwavering commitment to societal good, Indegene Limited, the pioneering digital-first life sciences commercialization powerhouse listed on BSE (544172) and NSE (INDGN), has once again demonstrated its dedication to corporate social responsibility (CSR). As detailed in its Annual Report for the financial year 2024-25, the company not only met but exceeded its statutory CSR obligations, channeling a robust Rs 3.24 crore into impactful projects that align with its mission to solve complex healthcare challenges. This spending surpasses the mandated 2% of average net profits, pegged at Rs 3.22 crore, reflecting a proactive approach to community upliftment in an industry often focused on innovation and profitability.
With a turnover of Rs 1,184 crore and a net worth standing tall at Rs 1,888 crore, Indegene’s financial health underscores its capacity to give back generously. The company’s agile model, blending healthcare expertise with cutting-edge technology, extends beyond product launches for biopharma and biotech giants—it’s now a force for positive change in underserved communities. As the world grapples with healthcare disparities, Indegene’s CSR efforts shine as a beacon, proving that business success and social empathy can walk hand in hand.
***
Financial Backbone of CSR Drive
At the heart of Indegene’s CSR strategy lies a solid financial foundation, as mandated by Section 135 of the Companies Act, 2013. The company’s average net profit for the relevant period clocked in at Rs 161.06 crore, triggering a CSR obligation of 2%—translating to Rs 3.22 crore. With no surplus from prior years or set-offs to adjust, this figure represented the full commitment for FY 2024-25. Yet, Indegene went further, allocating and spending Rs 3.24 crore on a mix of ongoing and new projects, creating an excess of Rs 0.02 crore available for carry-forward into future years.
This overachievement isn’t accidental; it’s a reflection of strategic planning amid a booming sector. Indegene’s life sciences focus—empowering biopharma, emerging biotech, and medical device firms to launch products with speed and precision—has fueled this growth. No administrative overheads or impact assessments diluted the spend, ensuring every rupee directly fueled community programs. As healthcare evolves digitally, Indegene’s CSR investments mirror this ethos, prioritizing efficiency and measurable outcomes.
***
| Key Fact | Value (in Rs. Crore) | Details |
|---|---|---|
| Average Net Profit | 161.06 | As per Section 135(5) of Companies Act, 2013 |
| 2% CSR Obligation | 3.22 | Mandatory spend based on average net profit |
| Total CSR Obligation (FY 2024-25) | 3.22 | No surplus or set-off from prior years |
| Amount Spent on CSR Projects | 3.24 | Includes ongoing and other projects |
| Administrative Overheads | 0 | Nil expenditure |
| Impact Assessment Spend | 0 | Not applicable |
| Total Amount Spent | 3.24 | Full allocation utilized |
| Unspent Amount | 2.49 | Transferred to Unspent CSR Account on 25 April 2025 |
| Excess Amount for Set-Off | 0.02 | Available for succeeding financial years |
| Turnover (FY 2024-25) | 1,184 | In Rs. Million (converted to Crore) |
| Net Worth (as on 31 March 2025) | 1,888 | In Rs. Million (converted to Crore) |
| CSR Committee Meetings | 1 | Held on 24 January 2025; Full attendance |
| Unspent Balance (31 March 2025) | 0.80 | Subsequently transferred to CSR bank account |
| Surplus from Prior Years | 0 | Nil claimed or carried forward |
Breaking Down the Spend
Diving deeper into the numbers, Indegene’s total CSR expenditure for the year reached Rs 3.24 crore, encompassing both ongoing initiatives and fresh endeavors. This figure breaks down neatly: the full amount went toward project implementation, with zero leakage into overheads or evaluations, as impact assessments were deemed not applicable under the rules.
A closer look reveals nuances in execution. While Rs 0.75 crore was marked as the total spent for the financial year in one ledger view—possibly tied to immediate disbursements—the broader project spend confirms the Rs 3.24 crore commitment. However, an unspent balance of Rs 2.49 crore highlights areas where funds await deployment, transferred promptly to a dedicated Unspent CSR Account on April 25, 2025, in line with regulatory timelines. No transfers were made to Schedule VII funds, keeping resources fluid for direct impact.
This meticulous tracking ensures transparency, a hallmark of Indegene’s operations. The excess spend of Rs 0.02 crore, calculated as the difference between actual outlay and obligation, positions the company favorably for the next fiscal, allowing seamless continuity without dipping into fresh profits.
***
Governance at the Helm
Steering this CSR ship is a well-constituted committee that embodies diverse expertise and accountability. As of March 31, 2025, Indegene’s CSR Committee—fully compliant with Section 135—includes four members: two executive directors, one non-executive, and one independent director. Chaired by Manish Gupta, who also serves as Chairman of the Board, CEO, and Chief Executive Director, the panel met once during the year on January 24, 2025. Quorum was present, with all four members attending, including the sole independent director, Mr. Pravin Udhyavara Bhadya Rao.
Attendance was impeccable: Dr. Rajesh Bhaskaran Nair (non-executive member), Dr. Sanjay Suresh Parikh (executive member), and Chairman Gupta all marked present, fostering collaborative decision-making. This single, focused meeting underscores efficiency—discussing allocations, progress, and alignments with national priorities—without the bloat of frequent gatherings. It’s a lean, mean governance machine, ensuring CSR isn’t a checkbox but a strategic pillar.
Notably, none of Indegene’s projects ventured into government-designated aspirational districts this year, though the company remains open to such expansions. The unspent balance as of March 31, 2025, stood at Rs 0.8 crore, swiftly moved to the bank account post-year-end, following a similar Rs 1 crore transfer from FY 2023-24 on April 16, 2024.
***
Echoes from Prior Years
Indegene’s CSR journey isn’t a one-year sprint; it’s a marathon built on lessons from the past. Reviewing the preceding three financial years paints a picture of steady progress and prudent management. In FY-1 (likely 2021-22), Rs 1.04 crore was transferred to the Unspent CSR Account, with Rs 0.50 crore spent that year, leaving Rs 0.54 crore for future use—no deficiencies noted.
FY-2 saw Rs 0.89 crore initially transferred, but balances adjusted to Rs 0.44 crore spent fully, closing the loop with nil remaining. By FY-3, Rs 0.68 crore was handled without unspent carryovers, showcasing maturing processes. These efforts cumulatively built toward FY 2024-25’s overachievement, with no surpluses claimed from priors, emphasizing fresh, annual commitments.
This historical lens reveals Indegene’s evolution: from navigating early regulatory waters to now exceeding targets, all while maintaining zero deficiencies. It’s a narrative of growth, where past unspents fuel present impacts, ensuring no community wait is in vain.
***
Broader Impact in Healthcare’s Shadow
What does Rs 3.24 crore mean in the grand tapestry of Indegene’s world? As a company that equips biopharma innovators with domain smarts, tech wizardry, and agile ops to tackle healthcare’s thorniest issues, CSR becomes an extension of that ethos. Though specifics on projects aren’t detailed in the report—focusing instead on compliance—the spend likely bolsters education, health access, and skill-building in life sciences, aligning with Schedule VII priorities like poverty alleviation and environmental sustainability.
In an era where digital health bridges gaps for millions, Indegene’s contributions ripple outward. Imagine rural youth gaining biotech training or underserved clinics getting tech-enabled diagnostics—these are the human stories behind the crores. With no projects in aspirational districts this year, future expansions could target Naxal-affected or tribal belts, amplifying reach.
Chairman Manish Gupta’s sign-off as CSR Committee head reaffirms this vision: a leader not just in boardrooms but in building equitable futures. As Indegene scales globally, its CSR footprint grows, proving that precision in profits can equal precision in philanthropy.
***
Looking Ahead with Optimism
As FY 2024-25 closes with a surplus for set-off and a clean compliance slate, Indegene Limited stands poised for even bolder CSR strides. The Rs 0.02 crore excess, unclaimed from priors, offers a buffer for innovative pilots—perhaps AI-driven health literacy programs or biotech scholarships. With turnover surging and net worth fortified, the company’s 2% obligation will only climb, but so will its ambition.
In the competitive life sciences arena, where speed and efficiency define winners, Indegene’s CSR narrative adds a humane layer. It’s not just about launching products; it’s about launching possibilities for communities. As investors eye BSE and NSE tickers, this report whispers a larger truth: true commercialization includes societal scale-up. For stakeholders, partners, and the public, Indegene’s Rs 3.24 crore story is more than numbers—it’s a promise kept, a future invested.
(India CSR)
